Tobin Schilke - 09 Jan 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Jan 2023
Net transactions value
-$100,525
Form type
4
Filing time
10 Jan 2023, 19:06:54 UTC
Previous filing
03 Jan 2023
Next filing
23 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale $42,525 -1,701 -2.7% $25.00 60,877 09 Jan 2023 Direct F1
transaction RVNC Common Stock Sale $28,000 -1,000 -1.6% $28.00 59,877 09 Jan 2023 Direct F1
transaction RVNC Common Stock Sale $30,000 -1,000 -1.7% $30.00 58,877 09 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.